GEORGE MASON UNIVERSITY SCHOOL OF LAW. CHEMICAL PATENT PRACTICE SPRING 2013 Professors Shubin & Heaney
|
|
|
- Brendan Kenneth Marsh
- 6 years ago
- Views:
Transcription
1 GEORGE MASON UNIVERSITY SCHOOL OF LAW CHEMICAL PATENT PRACTICE SPRING 2013 Professors Shubin & Heaney There is no text assigned for this course. Students are expected to read the legal decisions listed prior to each class. January 9 Introduction/Inventorship Burroughs Wellcome v. Barr Labs., 32 U.S.P.Q. 2d 1915 (Fed. Cir. 1994) Streck Inc. v. Research & Diagnostics Systems Inc., Case No (Fed. Cir., Oct. 20, 2011) Teva Pharmaceutical Industries, Ltd. v. AstraZeneca Pharmaceuticals LP, Case No (Fed. Cir. Dec. 1, 2011) January 16 Inventorship Pannu v. Iolab, 47 U.S.P.Q. 2d 1657 (Fed. Cir. 1998) Hess v. ACS, 41 U.S.P.Q. 2d 1782 (Fed. Cir. 1997) Fina v. Ewen, 43 U.S.P.Q. 2d 1935 (Fed. Cir. 1997) Hitzmann v. Rutter, 58 U.S.P.Q. 2d 1161 (Fed. Cir. 2001) January 23 Restriction/Double-Patenting General Foods Corp. v. Studiengesellschaft Kohle GmbH, 23 U.S.P.Q. 2d 1839 (Fed. Cir. 1992) In re Kaplan et al., 229 U.S.P.Q. 678 (Fed. Cir. 1986) In re Braat, 19 U.S.P.Q. 2d 1289 (Fed. Cir. 1991) In re Berg, 46 U.S.P.Q. 2d 1226 (Fed. Cir. 1998) Eli Lilly & Co. v. Barr Laboratories, Inc., 58 U.S.P.Q. 2d 1869 (Fed. Cir. 2001) In re Metoprolol Succinate Patent Litigation (AstraZeneca v. KV Pharmaceutical), 83 U.S.P.Q. 2d 1545 (Fed. Cir. 2007) In re Basell Poliolefine Italia S.P.A., 547 F.3d 1371, 89 USPQ2d 1030 (Fed. Cir. 2009) Amgen, Inc. v. Hoffman-LaRoche, Ltd., 580 F. 3d 1340, 92 U.S.P.Q.2d 1289 (Fed. Cir. 2009) Boehringer Ingelheim GmbH v. Barr Laboratories, Inc., 592 F.3d 1340, 93 U.S.P.Q.2d 1417 (Fed. Cir. 2010)
2 Markush Claims In re Harnisch, 206 U.S.P.Q. 300 (C.C.P.A. 1980) Ex parte Hozumi, 3 U.S.P.Q. 2d 1059 (Bd App 1984) Abbott Laboratories v. Baxter Pharmaceutical Products, Inc., 67 U.S.P.Q. 2d 1191 (Fed. Cir. 2003) Conoco v. Energy and Environment Int l., 79 U.S.P.Q. 2d 1801 (Fed. Cir. 2006) January 30 Utility (101) Nelson v. Bowler, 206 U.S.P.Q. 881 (C.C.P.A. 1980) In re Brana, 34 U.S.P.Q. 2d 1436 (Fed. Cir. 1995) Cross v. Iizuka, 224 U.S.P.Q. 739 (CCPA 1985) In re Fisher, 76 U.S.P.Q. 2d 1225 (Fed. Cir. 2005) Metabolite Labs, Inc. v. Lab Corp of Am. Holdings, 71 U.S.P.Q (Fed. Cir. 2004), cert. Dismissed, 79 U.S.P.Q. 2d 1065 (S. Ct. 2006) PTO Revised Interim Utility Guidelines 66 FR (available on the PTO website) In re Bilski, 545 F.3d 943, 88 U.S.P.Q. 2d 1385 (Fed. Cir. 2008) Prometheus Labs. v. Mayo Collaborative Services, 581 F.3d 1336, 92 U.S.P.Q.2d 1075 (Fed. Cir. 2009) Classen Immunotherapies v. Biogen Idec, Case no (Fed. Cir. August 31, 2011) Association for Molecular Pathology v. U.S. Patent and Trademark Office, Case No (Fed. Cir. July 29, 2011) PTO Examiner Training Materials: Personalized Medicine (Given out in class) February 6 Product-by-Process Claims Scripps Clinic & Research Foundation v. Genentech, Inc., 18 U.S.P.Q. 2d 1001 (Fed. Cir. 1991) Atlantic Thermoplastics Co., Inc. v. Faytex Corp., 23 U.S.P.Q. 2d 1481 (Fed. Cir. 1992) Exxon Chemical Patents, Inc. v. Lubrizol Corp., 35 U.S.P.Q. 2d 1801 (Fed. Cir. 1995) Process Claims Eli Lilly v. American Cyanamid Co., 38 U.S.P.Q. 2d 1705 (Fed. Cir. 1996)
3 Jepson Claims In re Ehrreich and Avery, 200 U.S.P.Q. 504 (C.C.P.A. 1979) Preambles Corning Blass Works v. Sumitomo Electric USA., Inc., 9 U.S.P.Q. 2d 1962 (Fed. Cir. 1989) Catalina Marketing Int l. Inc., v. Coolsavings.com, 62 U.S.P.Q. 2d 1781 (Fed. Cir. 2002) Transition Phrases Ex parte Davis and Tuukkanen, 80 U.S.P.Q. 448 (P.O.B.A. 1949) PPG v. Guardian, 37 U.S.P.Q. 2d 1618 (Fed. Cir. 1996) February , Second Paragraph, Indefiniteness In re Swinehart, 169 U.S.P.Q. 226 (C.C.P.A. 1971) Solomon v. Kimberly Clark, 55 U.S.P.Q. 2d 1279 (Fed. Cir. 2000) Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd. 18 U.S.P.Q. 2d 1016 (Fed. Cir. 1991) Eiselstein v. Frank, 34 U.S.P.Q. 2d 1467 (Fed. Cir. 1995) Verve v. Crane, 65 U.S.P.Q. 2d 1051 (Fed. Cir. 2002) Sixth Paragraph Masco Corp. v. U.S., 64 U.S.P.Q. 2d 1182 (Fed. Cir. 2002) February , First Paragraph, Enablement In re Marzocchi, 169 U.S.P.Q. 367 (C.C.P.A. 1971) a close reading In re Angstadt, 190 U.S.P.Q. 214 (C.C.P.A. 1976) Genentech Inc. v. Novo Nordisk, 42 U.S.P.Q. 2d 1001 (Fed. Cir. 1997) Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd. 18 U.S.P.Q. 2d 1016 (Fed. Cir. 1991) Pharmaceutical Res., Inc. v. Roxane Labs., Inc., Slip Op WL (Fed. Cir unpublished) In re Wands, 8 U.S.P.Q.2d 1400 (Fed. Cir. 1988) In re Vaeck, 20 U.S.P.Q (Fed. Cir. 1991) Enzo Biochem Inc. v. Calgene Inc., 52 U.S.P.Q. 2d 1129 (Fed. Cir. 1999) Amgen v. Hoechst, 65 U.S.P.Q.2d 1385 (Fed. Cir. 2003)
4 February , First Paragraph, Written Description In re Wertheim et al., 191 U.S.P.Q. 90 (C.C.P.A. 1976) In re Johnson, 194 U.S.P.Q. 187 (C.C.P.A. 1977) Ex parte Grasselli, 231 U.S.P.Q. 394 (Bd. App 1986) In re Grasselli, 138 F. 2d 453 (unpublished) (Fed. Cir. 1984) In re Driscoll, 195 U.S.P.Q. 434 (C.C.P.A. 1977) Fujikawa v. Wattanasin, 39 U.S.P.Q. 2d 1895 (Fed. Cir. 1996) Union Oil v. Atlantic Richfield, 54 U.S.P.Q. 2d 1227 (Fed. Cir. 2000) Purdue Pharma v. Faulding, 56 U.S.P.Q. 2d 1481 (Fed. Cir. 2000) Chiron v. Genentech, 363 F.3d 1247, 1254, 70 USPQ2d 1321, (Fed. Cir. 2004) PTO Written Description Training Materials (Revision 1: 3/25/08) (available on the PTO website) Written Description: incorporation by reference Southern Clay Products v. United Catalysts, 64 U.S.P.Q. 2d 1606 (Fed. Cir. 2002) March 6 Written Description (or not?) Regents of University of California v. Eli Lilly, 119 F.3d 1559, 43 U.S.P.Q. 2d 1398 (Fed. Cir. 1997) Enzo Biochem v. Gen-Probe Inc., 63 U.S.P.Q (Fed. Cir. 2002) Moba v. Diamond, 66 U.S.P.Q. 2d 1429 (Fed. Cir. 2003) University of Rochester v. G.D. Searle and Co., Inc., 69 U.S.P.Q. 2d 1886 (Fed. Cir. 2004) Chiron Corp. v. Genentech Inc., 70 U.S.P.Q. 2d 1321 (Fed. Cir. 2004) Metabolite Labs, Inc. v. Lab Corp. of Am. Holdings, 71 U.S.P.Q. 2d 1081 (Fed. Cir. 2004), cert. dismissed, 79 U.S.P.Q. 2d 1065 (S.Ct. 2006) Univ. of Rochester v. G.D. Searle & Co., 71 U.S.P.Q. 2d 1545 (Fed. Cir. 2004) In re Alonso, 545 F.3d 1015, 88 U.S.P.Q.2d 1849 (Fed. Cir. 2008) Ariad v. Lilly, 560 F.3d 1366, 90 U.S.P.Q.2d 1549 (Fed. Cir. 2009) March 13 NO CLASS March , First Paragraph, Best Mode Bayer v. Schein Pharmaceuticals, 64 U.S.P.Q. 2d 1001 (Fed. Cir. 2002) Chemcast Corp. v. Arco Industries Corp., 16 U.S.P.Q. 2d 1033 (Fed. Cir. 1990)
5 Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., 18 U.S.P.Q. 2d 1016 (Fed. Cir. 1991) Dana Corp. v. IPC Ltd. Partnershhip, 8 U.S.P.Q. 2d 1692 (Fed. Cir. 1988) Randomex Inc. v. Scopus Corp., 7 U.S.P.Q. 2d 1050 (Fed. Cir. 1988) Wahl Instruments v. Acvious, 21 U.S.P.Q. 2d 1123 (Fed. Cir. 1991) Glaxo Inc. v. Novopharm Ltd., 52 F.3d 1043, 34 U.S.P.Q.2d 1565 (Fed. Cir. 1995) The America Invents Act Wither 35 USC 102? 35 U.S.C. 102 (2011): See USPTO Website March 27 Anticipation In re Donohue, 226 U.S.P.Q. 619 (Fed. Cir. 1985) In re Schoenwald, 22 U.S.P.Q. 2d 1671 (Fed. Cir. 1992) In re Petering, 133 U.S.P.Q. 275 (C.C.P.A. 1962) In re Ruschig, 145 U.S.P.Q. 274 (C.C.P.A. 1965) Titanium Metals Corp. v. Banner, 227 U.S.P.Q. 73 (Fed. Cir. 1985) Atlas v. Ireco, 51 U.S.P.Q. 2d 1943 (Fed. Cir. 1999) In re Cruciferous Sprout Lititation, 64 U.S.P.Q. 2d 1202 (Fed. Cir. 2002) Schering v. Geneva, 67 U.S.P.Q. 2d 1664 (Fed. Cir. 2003) April 3 Obviousness (Although not specifically assigned, this topic assumes familiarity with the Supreme Court s decision in KSR Int l Co., v. Teleflex, Inc., 82 U.S.P.Q. 2d (US 2007) In re Grabiak, 226 U.S.P.Q. 870 (Fed. Cir. 1985) In re Jones, 21 U.S.P.Q. 2d 1941 (Fed. Cir. 1992) In re Lalu, 223 U.S.P.Q (Fed. Cir. 1984) In re Baird, 29 U.S.P.Q. 2d 1550 (Fed. Cir. 1994) Daiichi Sankyo Co., Ltd. V. Apotex, Inc., 84 U.S.P.Q. 2d 1285 (Fed. Cir. 2007) Takeda Chemical Ind., Ltd. V. Alphapharm Pty., Ltd., 84 U.S.P.Q. 2d 1197 (Fed. Cir. 2007) Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 82 U.S.P.Q. 2d 1852 (Fed. Cir. 2007) Pfizer, Inc. v. Apotex, Inc., 82 U.S.P.Q. 2d 1321 (Fed. Cir. 2007) In re Kubin, 561 F.3d 1351, 90 USPQ2d 1417 (Fed. Cir. 2009) Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.teleflex: Federal Register /Vol. 75, No. 169 /Wednesday, September 1, 2010 (Also available on the PTO website.)
6 April 10 Obviousness *Rule 132 Declarations In re Soni, 34 U.S.P.Q. 2d 1684 (Fed. Cir. 1995) In re Chupp, 2 U.S.P.Q. 2d 1437 (Fed. Cir. 1987) In re Zenitz, 142 U.S.P.Q. 158 (C.C.P.A. 1964) In re Davies, 177 U.S.P.Q. 381 (C.C.P.A. 1973) * Analogous Process In re Ochiai, 37 U.S.P.Q. 2d 1127 (Fed. Cir. 1995) Sanofi-Synthelabo v. Apotex Inc., (Fed. Cir. 12/12/08) Genetics Institute v. Novartis Vaccines, 655 F.3d 1291, (Fed. Cir. 2011) April 17 Biotech Issues (Guest Lecture?) Questions Review
Round Table Discussion: Shared Views and Perspectives on Outsourcing
Round Table Discussion: Shared Views and Perspectives on Outsourcing IQ Drug Metabolism Leadership Group Pharmaceutical Industry Benchmarking CPSA Shanghai, April 17th, 2018 www.iqconsortium.org IQ: Collaboration
ICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
ABOUT THE REPORT. About the 3-Month Report
THE DIGEST OF BIOTECH JOB TRENDS IN MASSACHUSET TS QUARTERLY LIFE SCIENCES JOB MARKET REPORT (Abbreviated) Q2 2018 ABOUT THE REPORT About the 3-Month Report MassBioEd produces a Quarterly on biopharmaceutical
ICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
2. Cases and materials cited below. 3. Newly decided cases and other materials may be handed out during the semester.
THE GEORGE MASON UNIVERSITY SCHOOL OF LAW PROFESSOR: Michael V. O Shaughnessy SYLLABUS FOR PATENT & KNOW-HOW LICENSING (LAW 286-001) 2 CREDIT HOURS HAZEL HALL ROOM 222 FALL 2017 CONTACT INFORMATION: Michael
DOING THE RIGHT THING AND DOING THINGS RIGHT
2013 EUROPEAN MEETING OF ISMPP DOING THE RIGHT THING AND DOING THINGS RIGHT 22 23 January, 2013 st paul s 200 aldersgate london, UK Why Exhibit at, and Sponsor the European Meeting? Sponsors and exhibitors
ICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA. Tel: +1 (650)
Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA Tel: +1 (650) 328 2900 www.tri-takeda.com 2 3 4 5 www.tri-takeda.com Operations started April 2002
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION) Feedback from 58 Latin-American patient groups PUBLISHED JUNE 2016 Que las Compañias Farmacéuticas tengan relación
Ref: FOI/CAD/ID August Freedom of Information Act 2000
Ref: FOI/CAD/ID 3437 24 August 2016 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act
Dec LILLE, France. 7 th. edition. A 360 approach to source early-stage innovations in Life Sciences. Organised by: In collaboration with:
LILLE, France 4 th & 5 th Dec. 2018 7 th edition A 360 approach to source early-stage innovations in Life Sciences Organised by: In collaboration with: BioFIT at a glance BioFIT is the leading partnering
RMI Researched Medicines Industry Association
RMI Researched Medicines Industry Association Submission to: Medsafe On the: Proposed Clinical Trials Guidelines 30 November 2009 Contact Kevin Sheehy, Scientific and Technical Manager RMI, Level 8, 86
Hospitality and Gifts Register (declared in year)
2013-14 (declared in year) Date of event, receipt, etc Type (gift; hospitality; sponsorship ; etc.) Description Approx. Cost Company / Declined Declared by whom Title/ Directorate Other info 23.07.13 Gift
CME Information 2018 AAD SUMMER MEETING DIRECTLY SPONSORED BY THE AMERICAN ACADEMY OF DERMATOLOGY
MISSION The purpose of the American Academy of Dermatology (AAD) CME Program is to provide members with opportunities for life-long learning and assistance in fulfilling their maintenance of certification
D Start of quarterly EPAD Cohort recruitment update on EPAD website WP4 EPAD Cohort and EPAD Trials
www.ep-ad.org European Prevention of Alzheimer s Dementia Consortium Grant Agreement nº115736 D4.10 - Start of quarterly EPAD Cohort recruitment update on EPAD website WP4 EPAD Cohort and EPAD Trials V2.0
General information. Name: Colin Sainsbury
General information Name of Organisation ByrneWallace Contact information Head of Organisation Main contact Name: Catherine Guy (Managing Partner) Address: 88 Harcourt Street, Dublin 2 Telephone: 353 1
Member Employment/Current position Declared interests
Conflict of interest (COI) register National Heart Foundation of Australia (NHFA) and Cardiac Society of Australia and New Zealand (CSANZ) Australian Clinical Guidelines for the management of Atrial Fibrillation
Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project. Chris Chinn VP and Head of RWE
Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project Chris Chinn VP and Head of RWE The need for Pragmatic Clinical Trials Healthcare decision makers are searching
Ontario Public Drug Programs
Chapter 3 Section 3.09 Ministry of Health and Long-Term Care Ontario Public Drug Programs Chapter 3 VFM Section 3.09 1.0 Summary About four million Ontarians receive drug coverage through the Ontario Public
Multiple Sclerosis in Practice. An Expert Commentary with Fred D. Lublin, MD, FAAN. A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary with Fred D. Lublin, MD, FAAN A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and
September 2-3, 2013 Chengdu, China
Root Cause Investigations and Corrective Actions for GCP Compliance September 2-3, 2013 Chengdu, China Good Clinical Practice (GCP) is a compilation of best practices and quality standards to be applied
Cases EUROPEAN COURT OF JUSTICE COURT OF FIRST INSTANCE
EUROPEAN COURT OF JUSTICE 56/65 Société Technique Minière [1966] ECR 337 273 6 and 7-73, Commercial Solvents and Others v. Commission, ECR 223 (1974) 177 27/76, United Brands Company v. Commission, ECR
THE OPIOID EPIDEMIC: 49 TH. Complex problems, complex solutions. Executive Summary. Thursday, April 26, 2018, 1-4 pm SESSION
Executive Summary THE OPIOID EPIDEMIC: Complex problems, complex solutions Thursday, April 26, 2018, 1-4 pm The Gallery, Downtown Minneapolis Hilton and Towers About the Roundtable About: The Minnesota
3-Month Job Trend Report
1 The Digest of Biotech Job Trends In Massachusetts 3-Month Job Trend Report January - March 2016 About the 3-Month Report MassBioEd produces a 3-Month Report on biopharmaceutical job trends each quarter
SAVE $25 if registered by March 17 SPRING REFRESHER APRIL 12 & 13 SAINT PAUL RIVERCENTRE
SAVE $25 if registered by March 17 SPRING REFRESHER APRIL 12 & 13 SAINT PAUL RIVERCENTRE It s wonderful to reconnect with friends and colleagues from all over Minnesota. Taking a break from our busy practices
FEBRUARY 4 TH, 2017 PROGRAM CHAIRS REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA RESERVE YOUR SPACE TODAY! PLEASE CONTACT:
FEBRUARY 4 TH, 2017 REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA PROGRAM CHAIRS Dr. Carlos Eduardo Zúñiga Orlich Medical Oncologist President, Costa Rican Association of Medical Oncology (ACOMED)
KEY FACTS ON CORPORATE FOUNDATIONS
May 2009 KEY FACTS ON CORPORATE FOUNDATIONS Outlook for Corporate Foundation Giving Giving by the nation s nearly 2,500 grantmaking corporate foundations remained basically unchanged in 2008 at an estimated
What next for Life Sciences? Vir Lakshman
What next for Life Sciences? Vir Lakshman CEO&CFO Gipfel BioDeutschland Reutlingen, Germany 3 rd December 2015 Big pharma is making deals, not drugs FINANCIAL TIMES November, 25th 2015 Life Sciences M&A
Conflict of Interest Disclosure Form
I n s t i t u t i o n o f t h e U E M S a i s b l NAME : Florian Lordick AFFILIATION: University Cancer Center Leipzig organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement
TABLE OF AUTHORITIES * CASES. AT&T v. Iowa Utils. Bd., 525 U.S. 366 (1999) AT&T v. FCC, 487 F.2d 865 (2d Cir. 1973)...31
TABLE OF AUTHORITIES * CASES Page AT&T v. Iowa Utils. Bd., 525 U.S. 366 (1999)...31 AT&T v. FCC, 487 F.2d 865 (2d Cir. 1973)...31 *Accuracy in Media, Inc. v. FCC, 521 F.2d 288 (D.C. Cir. 1975)...24, 25,
Pragmatic Trial Designs Capturing Endpoints and Integrating Data from Non-Linked Sources
Pragmatic Trial Designs Capturing Endpoints and Integrating Data from Non-Linked Sources Matthew T. Roe, MD, MHS Duke Clinical Research Institute Conflict of Interest Statement Matthew T. Roe, MD, MHS
Boston University Expert Review Meeting on the Evaluation of Novartis Access
Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie
European Association for Cardiovascular Prevention and Rehabilitation A registered branch of the European Society of Cardiology
INDUSTRY PROSPECTUS European Association for Cardiovascular Prevention and Rehabilitation A registered branch of the European Society of Cardiology Welcome to EuroPRevent 2009, the European meeting place
ALI-ABA Course of Study Product Distribution and Marketing June 22-24, 2011 Philadelphia, Pennsylvania
1023 ALI-ABA Course of Study Product Distribution and Marketing June 22-24, 2011 Philadelphia, Pennsylvania True Grit: Dealer Determination and Refusal to Deal By Richard J. Wegener Fredrikson & Byron,
Health and Life Sciences Committee. Advancing the ASEAN Post-2015 Health Development Agenda
Health and Life Sciences Committee Advancing the ASEAN Post-2015 Health Development Agenda Introduction The US-ASEAN Business Council s Health and Life Sciences (HLS) Committee is comprised of multinational
ICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
Member Organizations by Alpha
Member Organizations by Alpha August 2018 AAAHC Institute for Quality Improvement AARP Abbott ABIM Foundation Academic Pediatric Association Academy of Managed Care Pharmacy Academy of Nutrition and Dietetics
We support efforts that target specific abusive behavior, and we look forward to continuing to work with you toward that end.
April 28, 2014 The Honorable Patrick Leahy The Honorable Chuck Grassley Chairman Ranking Member Committee on the Judiciary Committee on the Judiciary United States Senate United States Senate Washington,
Gifts and Hospitality Register
Gifts and Hospitality Register Employees of the CCG may accept gifts, sponsorship and/or hospitality under certain circumstances, which are outlined in the Standards of Business Conduct Policy. In the
WITH A BUSINESS-FRIENDLY ENVIRONMENT AND LARGE INDUSTRY BASE, FLORIDA HAS THE PRESCRIPTION FOR YOUR SUCCESS.
E N T E R P R I S E F L O R I D A WHY FLORIDA? WITH A BUSINESS-FRIENDLY ENVIRONMENT AND LARGE INDUSTRY BASE, FLORIDA HAS THE PRESCRIPTION FOR YOUR SUCCESS. Florida is home to the nation s #2 largest medical
Member Organizations by Alpha
Member Organizations by Alpha January 2018 AAAHC Institute for Quality Improvement AARP Abbott ABIM Foundation Academic Pediatric Association Academy of Managed Care Pharmacy Academy of Nutrition and Dietetics
Drug Innovations Coming From Outside Big Pharma
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/drug-innovations-coming-from-outside-bigpharma/3524/
PROMOTIONAL AND SPONSORSHIP OPPORTUNITIES
PROMOTIONAL AND SPONSORSHIP OPPORTUNITIES THE 49 TH UNION WORLD CONFERENCE ON LUNG HEALTH 24 27 OCTOBER 2018. THE HAGUE, THE NETHERLANDS worldlunghealth.org JOIN US AT THE 49 TH UNION WORLD CONFERENCE
Jing Ma, Xuefeng Wang, Donghua Zhu and Xiao Zhou School of Management and Economics, Beijing Institute of Technology, Beijing, China
Jing Ma, Xuefeng Wang, Donghua Zhu and Xiao Zhou School of Management and Economics, Beijing Institute of Technology, Beijing, China majing881003@163.com GTM Conference Sep. 25 2013 Introduction Collaborative
presents OHIO biomedical and pharma career fair April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet
presents OHIO biomedical and pharma career fair 2013 April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet Exhibitors Aerotek Scientific Alliance Scientific Amylin Ohio Aptalis Pharmatech Cardinal Health Diagnostic
Patient Adherence & Engagement Summit 2009
6th Annual Patient Adherence & Engagement Summit 2009 Two Day Conference October 26-27 Crowne Plaza, Philadelphia, USA Benchmark your adherence strategies against our EXPERT SPEAKERS: Rich Baron Executive
Member Organizations by Council
Member Organizations by Council April 2018 Consumer Council AARP AFL-CIO American Cancer Society Cancer Action Network American Federation of Teachers Nurses and Healthcare Professionals Center for Patient
Judicial Review of Agency Guidance. Kirsten L. Nathanson Crowell & Moring LLP November 9, 2011
Judicial Review of Agency Guidance Documents Kirsten L. Nathanson Crowell & Moring LLP November 9, 2011 Overview» Setting the Stage» Jurisdictional Hurdles» Is It A Rule?» Obtaining A Ruling on Substance
Arab Expatriate Scientists and the Science and Technology Revolution in the Arab World
Arab Expatriate Scientists and the Science and Technology Revolution in the Arab World Shaker A. Mousa, PhD, MBA, FACC, FACB Pharmaceutical Research Institute (PRI) Albany College of Pharmacy and Health
Australian Biomedical & Healthcare
Australian Biomedical & Healthcare A Wealth of Investment Opportunities Sam Guthrie Senior Trade Commissioner Australian Trade & Investment Commission Why Australia 1 4 th largest economy in the Asia region
Pew/NCSL Panel on Investing in Life Sciences Boston Federal Reserve Bank
Pew/NCSL Panel on Investing in Life Sciences Boston Federal Reserve Bank Barry Bluestone Professor, Northeastern School of Public Policy Senior Fellow, The Boston Foundation February 24, 2017 Introduction
August 27-30, 2009 New York, NY
PRI-MED SYMPOSIA Pri-Med New York CONFERENCE & EXHIBITION August 27-30, 2009 New York, NY Earn up to 17 AMA PRA Category 1 Credit(s) Pre-Conference Symposia Day Track 1 Thursday, August 27, 2009 6:30 AM
Content EUROHEARTCARE ORGANISATION... 3 EUROHEARTCARE FACTS & FIGURES... 4 GENERAL MEETING INFORMATION... 5 INDUSTRY PARTNERS PARTICIPATION...
INDUSTRY PROSPECTUS Content EUROHEARTCARE ORGANISATION... 3 EUROHEARTCARE FACTS & FIGURES... 4 GENERAL MEETING INFORMATION... 5 INDUSTRY PARTNERS PARTICIPATION... 6 INDUSTRY ACTIVITIES AT EUROHEARTCARE
Emory Research A-to-Z
Emory Research A-to-Z May 17, 2012 COI EHSO IACUC IDS IRB OCR ORAIT ORC OSP OTT Agenda Research Administration Announcements New COI Policy: Update Industry Initiated Clinical Research: Pre-Award Pre-Award
Osteoporosis Stakeholders List
Osteoporosis Stakeholders List A. Menarini Pharma UK Adults Strategy and Commissioning Unit Age Concern Cymru Age Concern England Airedale General Hospital All About Nocturnal Enuresis Team All Wales Dietetic
Lower urinary tract symptoms - Stakeholder List:
Lower urinary tract symptoms - Stakeholder List: Abbott Laboratories Limited Afiya Trust, The Age Concern England Aintree University Hospitals NHS Foundation Trust Airedale Acute Trust Airedale and Bradford
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Single Technology Appraisal Vortioxetine for the treatment of major Provisional matrix of consultees and commentators Manufacturers/sponsors
Atrial Fibrillation (Review) guideline
Atrial Fibrillation (Review) guideline Stakeholder List: Academic Cardiology Aintree University Hospitals NHS Foundation Trust Airedale NHS Foundation Trust Anglia Stroke and Heart Network Anticoagulation
MEDICAID REBATE SUMMIT
A strategic-level, interactive forum guided by conference industry veterans and an advisory board, with representation from Mylan Pharmaceuticals Inc., Eli Lilly & Co., Wockhardt USA and Daiichi Sankyo,
Schaghticoke Tribal Nation v. Kent School Corporation Inc.
Public Land and Resources Law Review Volume 0 Case Summaries 2014-2015 Schaghticoke Tribal Nation v. Kent School Corporation Inc. Lindsey M. West University of Montana School of Law, mslindseywest@gmail.com
NUCLEAR ENERGY LAW UNIVERSITY OF HOUSTON LAW CENTER FALL 2010 SEMESTER (AUGUST 23, 2010) INTRODUCTION
NUCLEAR ENERGY LAW UNIVERSITY OF HOUSTON LAW CENTER FALL 2010 SEMESTER (AUGUST 23, 2010) Course No. 6379 Section No. 35265 (3.0 Credit Hours) MW; 6:00-7:30 p.m. Room 215 TU2 Robert S. Ballentine, LL.M.
United States Court of Appeals
United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued February 2, 2017 Decided April 21, 2017 No. 16-5174 CONSUMER FINANCIAL PROTECTION BUREAU, APPELLANT v. ACCREDITING COUNCIL FOR
Conference The Diplomat Hollywood, FL March 12 14, 2015
Sponsor and Exhibitor Prospectus 2015 Annual CANCER CARE The Diplomat Hollywood, FL March 12 14, 2015 Dates March 12 14, 2015 Reservation Forms Included: 1 Sponsor Level Application 2 Exhibit Space Application
Law The Law of Hazardous Waste: CERCLA, RCRA, & Common Law Claims (Fall 2008) Syllabus
Law 273.4 The Law of Hazardous Waste: CERCLA, RCRA, & Common Law Claims (Fall 2008) Units: 3 CCN (2Ls/3Ls): 49694 Instructor: Robert D. Infelise Email: rinfelise@law.berkeley.edu Location: 115 Boalt Time:
Historical Background. S. Krimsky
1 Toward Academic Capitalism The decade of the 1980s was a watershed for the university sector. Academia became highly commercialized, especially notable in the life sciences. This effect has been in great
Case 1:17-cv WHP Document 99 Filed 11/27/17 Page 1 of 9 : : : : : : : : : : :
Case 117-cv-07232-WHP Document 99 Filed 11/27/17 Page 1 of 9 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK MICHAEL B. DONOHUE, et al., Plaintiffs, -against- CBS CORPORATION, et al. Defendants.
Healthcare Leadership Development
Healthcare Leadership Development CultureSync s work is absolutely critical to anyone seeking to change their company s fortunes. Adaptable to any company and any leader, their advice shows you how to
The Interface between Universities Public Research Institutions and SMEs
Topic 14 The Interface between Universities Public Research Institutions and SMEs Training of Trainer s Program, Teheran 10 June 2015 By Matthias Kuhn, MBA University of Geneva, Unitec, Switzerland 1 1
CONVERSATIONS PRIMARY CARE
Conversation in PC 2017 Cover 2.qxp_Cover 2/21/17 2:43 PM Page 1 CONVERSATIONS IN PRIMARY CARE Live Virtual Conference Saturday, March 4, 2017 Streaming Live From Fort Lauderdale, FL Provided by COPYRIGHT
DIA Meeting on Companion Diagnostics
DIA Meeting on Companion Diagnostics October 29-30 Washington, DC PROGRAM COMMITTEE: Miu Chau, PhD Regulatory Program Director Genentech, A Member of the Roche Group Jennifer Dudinak, PharmD Vice President
NLRB v. Community Medical Center
2011 Decisions Opinions of the United States Court of Appeals for the Third Circuit 8-3-2011 NLRB v. Community Medical Center Precedential or Non-Precedential: Non-Precedential Docket No. 10-3596 Follow
Preview EUR PEAN PHARMACO VIGILANCE CONGRESS
Preview ABOUT PEC Pharma Education Center S.r.l. warmly invites PV professionals from the world to the European Day 2nd Edition which will be held on November 29-30, 2018 in Milan, Italy. The field of
Science4Life started in 1998 with the idea of
Science4Life A German Initiative for Start-Ups in the Life Sciences and Chemistry by Uwe Gerlach Science4Life started in 1998 with the idea of providing unique support for potential entrepreneurs in the
Start-up Management as Technology Transfer within the Max-Planck- Society. Dr. Florian Kirschenhofer. Start-up Manager Max-Planck-Innovation GmbH
Dr. Florian Kirschenhofer Start-up Manager Max-Planck-Innovation GmbH Start-up Management as Technology Transfer within the Max-Planck- Society UN Conference, Geneva, 11th of April 2008 Max-Planck-Gesellschaft
11 th Annual Patent Law Institute
11 th Annual Patent Law Institute John Cabeca Director, West Coast Region United States Patent and Trademark Office April 27, 2017 2017 PTO Update: Agenda Quality Initiatives Pendency Reduction Examiner
ABOUT THE REPORT. About the 3-Month Report
THE DIGEST OF BIOTECH JOB TRENDS IN MASSACHUSET TS QUARTERLY LIFE SCIENCES JOB MARKET REPORT: Q4 2017 ABOUT THE REPORT About the 3-Month Report MassBioEd produces a 3-Month Report on biopharmaceutical
Emerging Challenges in Primary Care: 2018
Atlanta Simulcast 2018 Cover.qxp_Cover 5/11/18 1:38 PM Page 1 17th Annual Emerging Challenges in Primary Care: 2018 LIVE CONFERENCE Saturday, June 2, 2018 Broadcast Live From Atlanta, GA Jointly Provided
Improving medication adherence through technology: analyzing the managing meds video challenge
Skin Research and Technology 2014; 20: 62 66 Printed in Singapore All rights reserved doi: 10.1111/srt.12084 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Skin Research and Technology
PROSECUTING AND DEFENDING FEDERAL DRUG OFFENSES. JOSE ANGEL MORENO Assistant United States Attorney 1100 Matamoros, Suite 200 Laredo, Texas 78040
PROSECUTING AND DEFENDING FEDERAL DRUG OFFENSES JOSE ANGEL MORENO Assistant United States Attorney 1100 Matamoros, Suite 200 Laredo, Texas 78040 SELENA N. SOLIS 1 Assistant Federal Public Defender 700
Pulmonary Hypertension Summit 2017
Florida Pulmonary Hypertension Summit 2017 October 6 7, 2017 InterContinental Hotel and Bank of America Conference Center, Cleveland, OH Hilton Fort Lauderdale, Fort Lauderdale, FL Pulmonary Hypertension
Case 1:15-cv NMG Document 21 Filed 05/15/15 Page 1 of 6 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS
Case 1:15-cv-11583-NMG Document 21 Filed 05/15/15 Page 1 of 6 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS NATIONAL IMMIGRATION PROJECT OF THE NATIONAL LAWYERS GUILD and AMERICAN CIVIL LIBERTIES
Case 1:10-cv ESH -HHK Document 14 Filed 07/15/10 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:10-cv-01062-ESH -HHK Document 14 Filed 07/15/10 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA STATE OF GEORGIA, v. Plaintiff, ERIC H. HOLDER, JR., in his official
IN THE SUPREME COURT OF THE UNITED STATES. No YASER ESAM HAMDI AND ESAM FOUAD HAMDI, AS NEXT FRIEND OF YASER ESAM HAMDI, PETITIONERS
IN THE SUPREME COURT OF THE UNITED STATES No. 03-6696 YASER ESAM HAMDI AND ESAM FOUAD HAMDI, AS NEXT FRIEND OF YASER ESAM HAMDI, PETITIONERS v. DONALD RUMSFELD, SECRETARY OF DEFENSE, ET AL. ON PETITION
The New Corporate Integrity Agreements: What Did the Board Know and When Did They Know It?
The New Corporate Integrity Agreements: What Did the Board Know and When Did They Know It? Malcolm J. Harkins Center for Health Law Studies St. Louis University School of Law 2015 by Malcolm J. Harkins
Application Form CSANZ-BAYER Young Investigator Research Grants. Applicant Name. Project Title
2018 CSANZ-BAYER Young Investigator Research Grants Exclusively supported by an unrestricted research grant from Boehringer Ingelheim Application Form Applicant Name Project 1. APPLICANT DETAILS Name Current
session on Preparation
Mentoring Clinics 2016/20 Talk and One on One mentoring session on Preparation for 9th Call of Biotechnology Ignition Grant (BIG) for Entrepreneurs and Innovators Organized by Venturee Center, Pune POTENTIAL
THE TEXAS POLICY VOICE FOR HEALTHCARE AND BIOSCIENCE SINCE 1996
THE TEXAS POLICY VOICE FOR HEALTHCARE AND BIOSCIENCE SINCE 1996 THBI is the statewide advocacy and public policy organization representing the life sciences in Texas The mission of the Texas Healthcare
Follow this and additional works at: Part of the Business Commons
University of South Florida Scholar Commons College of Business Publications College of Business 4-22-1999 Medical research and the location of high-tech medical firms : summary report / : prepared for
HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery
www.hcmena.economist.com @EconomistEvents #hcmena HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery OCTOBER 13TH 2015 MADINAT JUMEIRAH, MINA A SALAM, DUBAI Explore a tangible
ICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
Ireland Future R&D Investment in a Small Open Economy Opportunities and Threats. Third KEI Workshop Helsinki
Ireland Future R&D Investment in a Small Open Economy Opportunities and Threats Third KEI Workshop Helsinki Presentation Outline: Celtic Tiger Phenomenon R&D and globalisation Case for change Opportunities
Case 1:15-cv RC Document 41-1 Filed 04/07/16 Page 1 of 17 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:15-cv-00802-RC Document 41-1 Filed 04/07/16 Page 1 of 17 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA FERRING PHARMACEUTICALS, INC., Plaintiff, v. SYLVIA M. BURWELL, et al.,
October 3-5, 2008 New York, NY
PRI-MED SYMPOSIA Pri-Med New York CONFERENCE & EXHIBITION October 3-5, 2008 New York, NY Earn up to 17 AMA PRA Category 1 Credit(s) Pre-Conference Symposia Day Schedule Track 1 Thursday, October 2, 2008
HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery
www.hcmena.economist.com @EconomistEvents #hcmena HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery OCTOBER 13TH 2015 MADINAT JUMEIRAH, MINA A SALAM, DUBAI Explore a tangible
Sponsor & Exhibitor Prospectus
23rd CONFERENCE Improving the Quality, Effectiveness, & Efficiency of Cancer Care March 22 24, 2018 Rosen Shingle Creek Orlando, Florida 201 Sponsor & Exhibitor Prospectus Exhibition Hall Dates March 22
Statisticians in the Pharmaceutical Industry Limited
Statisticians in the Pharmaceutical Industry Limited Business Plan 2010 12 Business Plan 2010-2012 Statisticians in the Pharmaceutical Industry Ltd Engage with PSI The Board of Directors wishes to encourage
2012 Global. R&D Funding Forecast. December 2011
December 2011 2012 Global R&D Funding Forecast U.S. Industry R&D Increases 3.8% to $280 Billion Growing Worldwide Emphasis on Basic Research Global R&D Spending to Increase 5.2% to $1.4 Trillion Increasing
Every Successful Venture Needs a Partner
Final Agenda EIGHTH ANNUAL Strategic Alliance Management CONGRESS COLLABORATIONS & IMPLEMENTATION FOR SUCCESS April 6-7, 2011 Crowne Plaza Philadelphia Downtown INAUGURAL Biopharma Licensing CONGRESS WHERE
Robert L. Charles, Esq.
CRADA Workshop Robert L. Charles, J.D., LL.M., M.P.H. Army Medical Research and Materiel Command Fort Detrick, Maryland (301) 619-7663 robert.charles@us.army.mil Robert L. Charles, Esq. Chief, Medical
Phillips Pharmaceuticals (Nigeria) Limited RC COMPANY PROFILE
COMPANY PROFILE A glimpse into the history and current operations of Phillips Pharmaceuticals Ltd. The past: Phillips International limited (formerly known as Phillips Harrison & Crossfield Limited), was